. This compound is an adenosine derivative with a 2,3-dihydrofuran ring structure that contains a 2-fluoro group. The resistance profile of GS-9148 is unique in that the inhibitor can select for the very rare Q151L mutation in HIV-1 RT as a pathway to resistance. Q151L is not stably selected by any of the approved nucleoside or nucleotide analogues; however, it may be a transient intermediate that leads to the related Q151M mutation, which confers resistance to multiple compounds that belong to this class of RT inhibitors. Here, we employed pre-steady-state kinetics to study the impact of Q151L on substrate and inhibitor binding and the catalytic rate of incorporation. Most importantly, we found that the Q151L mutant is unable to incorporate GS-9148 under single-turnover conditions. Interference experiments showed that the presence of GS-9148-diphosphate, i.e., the active form of the inhibitor, does not reduce the efficiency of incorporation for the natural counterpart. We therefore conclude that Q151L severely compromises binding of GS-9148-diphosphate to RT. This effect is highly specific, since we also demonstrate that another NtRTI, tenofovir, is incorporated with selectivity similar to that seen with wild-type RT. Incorporation assays with other related compounds and models based on the RT/DNA/GS-9148-diphosphate crystal structure suggest that the 2-fluoro group of GS-9148 may cause steric hindrance with the side chain of the Q151L mutant.
The DNA polymerase activity of HIV-1 reverse transcriptase (RT) is targeted by nucleos(t)ide analogue RT inhibitors [N(t)RTIs], which represent the backbone of frequently used drug regimens. N(t)RTIs compete with natural deoxynucleoside triphosphate (dNTP) pools for incorporation and cause chain termination. There are currently seven approved NRTIs available for the treatment of HIV-1 infection (7) . The only approved NtRTI, i.e., tenofovir, is a phosphonate with an acyclic linker attached to the adenine base (7) . An investigational NtRTI, GS-9148, has recently been shown to be active against HIV-1 in cell culture and to possess a promising resistance profile in addition to a low nephrotoxic potential (4, 5) . GS-9148 is the intracellularly metabolized form of the orally bioavailable phosphonate GS-9131 (29) (Fig. 1) . GS-9148 undergoes two phosphorylations to become GS-9148-diphosphate (GS-9148-DP), which, like tenofovir-DP, is the active metabolite that is incorporated by HIV-1 RT. In contrast to tenofovir, GS-9148 is composed of a 2Ј,3Ј-dihydrofuran that contains a 2Ј-fluoro group (2) (Fig. 1) .
In vitro selection experiments in cell culture revealed the emergence of two different resistance pathways. The compound selects either for Q151L, with high-level resistance to GS-9148 (16) , or for a combination of K70E, D123N, and T165I, which shows low-level resistance to GS-9148 (17) . Q151L is a potential intermediate in the development of the Q151M cluster that is associated with resistance to multiple NRTIs (22) . However, the Q151L mutation is severely compromised in replication capacity, which helps to explain its low prevalence (12) . While Q151M shows low-level resistance to GS-9148, Q151L shows specific high-level resistance to this compound in phenotypic susceptibility assays (17) . Interestingly, Q151L shows hypersusceptibility to tenofovir in cell culture (16) .
Resistance to N(t)RTIs is associated with two major biochemical mechanisms: certain mutations discriminate against the inhibitor at the level of binding and incorporation, while other mutations have been shown to excise the incorporated inhibitor in the presence of ATP, which can act as a pyrophosphate (PP i ) donor (23) . To elucidate the underlying biochemical mechanisms of resistance for Q151L RT to GS-9148, we employed pre-steady-state kinetics, which revealed that Q151L severely compromises the binding of GS-9148-DP. Experiments with related compounds point to a possible steric hindrance associated with the 2Ј-fluoro group of the sugar moiety, which was confirmed by modeling studies.
MATERIALS AND METHODS
Enzymes and nucleic acids. Heterodimeric reverse transcriptase p66/p51 of HIV-1 (HXB2) was expressed and purified as previously described (19) . Mutant enzymes were generated through site-directed mutagenesis using a Stratagene Quick-Change kit according to the manufacturer's protocol. Oligodeoxynucleotides used in this study were chemically synthesized and purchased from Invit-rogen Life Technologies (Carlsbad, CA). The template sequence was from primer 42D, 5ЈGGATAAAGATTCAGTCTAGGATGTATGTTTAGTAGGT ACATAACTATCTATTGATACAGACCTAAAACAA. The initial primer used in DNA synthesis inhibition assays was 20D, 5ЈTGTTTTAGGTCTGTAT CAAT. For pre-steady-state kinetic analysis and other experiments, we examined incorporation at the ϩ3 position using the primer 20Dϩ3, 5ЈTTGTTTTAGGT CTGTATCAATAG.
Primers were 5Ј radiolabeled and gel purified as previously described (14) . Labeling was performed using polynucleotide kinase purchased from Fermentas Life Science (Burlington, Ontario, Canada) and [␥- 32 P]ATP purchased from PerkinElmer (Waltham, MA). Deoxynucleotides were purchased from Fermentas Life Science. 2Ј-modified adenosine analogues were purchased from Trilink Biotechnologies (San Diego, CA). GS-9148-DP and (R)-9-(2-phosphonylmethoxypropyl)adenine-DP (PMPA-DP, tenofovir-DP) were provided by Gilead Sciences, Inc.
DNA synthesis inhibition assay. The 5Ј-labeled 20D primer (50 nM) was heat annealed with 100 nM 42D template. The DNA/DNA hybrid was incubated with 250 nM HIV-1 RT in a buffer containing 50 mM Tris-HCl, pH 7.8, 50 mM NaCl, and 0.2 mM EDTA with 1 M each of the four dNTPs in the presence or absence of 10 M chain terminator (GS-9148-DP, tenofovir-DP, or ddATP). The mixture was incubated at 37°C and the reaction started by the addition of 6 mM MgCl 2 . At 10 min, the reaction was stopped by the addition of a 2-volume excess of formamide buffer containing trace amounts of bromophenol blue and xylene cyanol, and the mixture was heat denatured at 95°C for 5 min. The products of DNA synthesis were resolved on a 12% denaturing polyacrylamide gel by electrophoresis and visualized by phosphorimaging.
Nucleotide incorporation assays with 2-modified adenosine analogues. Structure-activity relationship (SAR) experiments were performed as was the DNA synthesis inhibition assay, using the 20Dϩ3 primer and a time point of 10 s with 1 M dATP or 1 mM araATP, 2Ј-azido-2Ј-dATP, or 2Ј-fluoro-2Ј-dATP. Samples were resolved and visualized as described above. Incorporation of the 2Ј-modified adenosine analogues by each of the mutant enzymes was normalized to incorporation of dATP by that enzyme under reaction conditions. Pre-steady-state kinetics. Assays were performed as described previously (9, 14, 31) . 5Ј-labeled 20Dϩ3 primer (100 nM) was heat annealed with 200 nM 42D template. The DNA/DNA hybrid was incubated with 500 nM HIV-1 RT in a buffer containing 50 mM Tris-HCl, pH 7.8, 50 mM NaCl, and 6 mM MgCl 2 . Substrate (dATP or analogues) was prepared in the same buffer as the RT-P/T (primer/template), and the reaction was started and stopped by computer control using a Kintek RFQ-3 Quench Flow instrument (Austin, TX). Equal volumes of 15 l RT-P/T and substrate were mixed in this manner for times ranging from 0.015 s to 2.0 s, and the reaction was stopped by the addition of excess 0.5 M EDTA. Substrate concentrations ranged from 780 nM to 200 M for dATP, GS-9148-DP, tenofovir-DP, and ddATP. Samples were diluted in formamide buffer containing trace amounts of bromophenol blue and xylene cyanol and heat denatured at 95°C for 5 min. Samples were resolved and visualized as described above. Incorporation was quantified using ImageQuant (GE Healthcare) as (product/total) ϫ 100 nM, and results were plotted in Prism 4.0 using the nonlinear regression for one-phase exponential association to the equation
where t is time, A is amplitude of product formed, and k obs is the observed rate at a given concentration of substrate. Rates obtained from each concentration of substrate were replotted against the concentration of substrate by using nonlinear regression for Michaelis-Menten with the equation
, which allows for the determination of the kinetic constants k pol (rate of nucleotide incorporation) and K d (dissociation constant) for the chemical reaction of nucleotide incorporation as previously described (9, 14, 31).
ATP-mediated excision of chain-terminated primers. 20Dϩ3 primer was chain terminated using wild-type (WT) RT with tenofovir-DP or GS-9148-DP and gel purified as previously described (30) . These chain-terminated primers were then heat annealed to a 2-fold excess of template 42D, and the resulting hybrid (50 nM) was incubated with 250 nM RT (WT or K65R or Q151L mutant) in buffer containing 50 mM Tris-HCl, pH 7.8, 50 mM NaCl, and 0.2 mM EDTA. A rescue mix containing 1 M dATP, 1 M dTTP, 10 M ddGTP, and either 3.1 to 200 M inorganic pyrophosphate or 3.2 mM ATP as a pyrophosphate donor for the excision reaction was prepared in the same buffer as the reaction mixture. ATP was treated with inorganic pyrophosphatase to eliminate contaminating PP i . Reactions were performed in a final volume of 20 l and initiated with the addition of 6 mM MgCl 2 , and 2-l samples were taken from 30 s to 20 min for PP i and 5 min to 90 min for ATP. Samples were resolved and visualized as described above. A 100% extension of non-chain-terminated primer 20Dϩ3 was observed for all mutants under these reaction conditions, thus eliminating differences in incorporation. Correction for minimal (Ͻ10%) extension of chainterminated primer 20Dϩ3 in the absence of a PP i donor indicated that any extension products under experimental conditions represented products of the excision reaction. Results were analyzed as described above; results with ATP were analyzed at a single concentration and fitted to a one-phase exponential with the equation Molecular modeling. Molecular modeling of the Q151L and Q151M mutants bound to GS-9148-DP was based on the ternary crystal structure of WT HIV-1 RT bound to GS-9148-DP (Protein Data Bank [PDB] code 3KK1) (18) . The X-ray model was converted into its corresponding minimized model. All residues within a 6-Å sphere of GS-9148-DP were selected and minimized using Sybyl (Sybyl molecular modeling software, version 6.8; Tripos Inc., St. Louis, MO). Q151L and Q151M mutants were generated using methods previously described (34) . The modified side-chain conformations of the Q151L and Q151M mutants were then minimized.
RESULTS
Biochemical resistance profile of GS-9148-DP. Inhibition of DNA synthesis with the adenosine analogues GS-9148-DP, tenofovir-DP, and ddATP was evaluated with purified RT enzymes using a short DNA template (Fig. 2) . Full-length-product formation was initially monitored at a single concentration of inhibitors with WT RT and enzymes containing mutation Q151L, Q151M, or K65R. K65R confers decreased susceptibility to both tenofovir and didanosine (ddI, i.e., the prodrug of ddATP) and was included in this study for comparative purposes.
The presence of 10 M each adenosine analogue studied in the context of WT RT resulted in significant decreases in full-length-product formation and accumulation of chain-terminated sites opposite the complementary thymidines. GS-9148-DP and tenofovir-DP showed similar levels of inhibition under these conditions, with subtle increases in early chain termination with tenofovir-DP. The presence of ddATP showed the most efficient inhibitory effects, which resulted in greater accumulation of chain termination products at position nϩ1 and no observable full-length product. These results are consistent with the 50% effective concentrations (EC 50 s) of the three drugs (5). In cell culture, K65R is associated with reduced susceptibility to tenofovir and ddI, but a K65R mutant retains its susceptibility to GS-9148 (5). Here we show, as expected, that the K65R mutation in HIV-1 RT decreases sensitivity to ddATP, now with visible full-length-product formation. The K65R mutant appears least sensitive to tenofovir-DP, with the largest amount of full-length product. The mutant also displayed clear chain termination in the presence of GS-9148-DP, although full-length-product formation increased noticeably compared with that for WT RT. However, it is conceivable that K65R may also diminish excision of GS-9148, as has been shown for zidovudine (AZT) and tenofovir (20, 27) , which would help to explain the lack of reduced susceptibility data obtained in cell culture (5) .
The Q151L mutant RT shows the strongest resistance to inhibition by GS-9148-DP. Inhibition of DNA synthesis is essentially not seen under these conditions. This effect is highly specific, as the activity of tenofovir-DP and ddATP is almost identical to that seen with WT RT. It appears as if Q151L can cause even subtle increases in inhibition with tenofovir-DP, while subtle reductions in inhibition are seen with ddATP. These patterns differ from those of the established Q151M mutant. Although the Q151M mutant displays decreased susceptibility to GS-9148-DP, it is more subtle than the result for the Q151L mutant (16), i.e., formation of the full-length product remains reduced, and chain termination is visible. The Q151M mutation also causes subtle reduction in inhibition with tenofovir-DP and ddATP.
Pre-steady-state kinetic analysis. We next employed presteady-state kinetics for single nucleotide incorporation events to translate our initial findings into quantitative terms. We measured the rate constant k pol and the equilibrium binding constant K d for the natural substrate dATP and each of the inhibitors GS-9148-DP, tenofovir-DP, and ddATP against WT RT and mutant enzymes (Table 1 ; also see WT RT incorporated the substrates with efficiencies in the order dATP Ͼ ddATP Ͼ tenofovir-DP Ͼ GS-9148-DP, although the differences among the inhibitors are subtle. A selectivity of 16.5 against GS-9148-DP is primarily the result of a 10-fold increase in K d with a minimal (Ͻ2-fold) decrease in k pol . Thus, a diminution in substrate affinity appears to be the major factor that reduces efficiency of incorporation. In contrast, a selectivity of 5 against ddATP is the result of a pronounced decrease in k pol , with no significant change in K d relative to that for the natural substrate dATP. Thus, in this case, substrate binding does not appear to be affected; rather, it is the rate-limiting step of the conformational closing of the thumb-and-finger loop over the nucleotide binding site or the chemical step that is compromised. A selectivity of 10.8 against tenofovir-DP indicates a mixture of changes in both K d and k pol values, suggesting that substrate binding as well as the conformational change or chemical step is compromised.
The K65R mutant caused reductions in the efficiency of incorporation of each of the three inhibitors. Incorporation of the natural substrate is approximately 2-fold reduced. The strongest effect is seen with tenofovir-DP. Changes in kinetic parameters translate into 6.1-fold resistance to this inhibitor, which is in accordance with previous reports of a k pol -mediated effect for the K65R mutant with tenofovir (10, 27) . Resistance to GS-9148-DP is less pronounced (2.9-fold), and resistance to ddATP is almost negligible (1.2-fold) .
The Q151L mutant showed approximately 10-fold reductions in efficiency of incorporation of the natural substrate dATP compared with that for WT RT. We were unable to measure incorporation of GS-9148-DP at concentrations up to 200 M, which is in agreement with the lack of inhibition of polymerization shown in Fig. 2 . The combined data suggest that Q151L literally prevents incorporation of this inhibitor under single-turnover conditions. In contrast, efficiency of incorporation of tenofovir-DP is slightly increased. In an attempt to elucidate the underlying mechanism of this exclusion, we employed an incorporation interference experiment to assess whether GS-9148-DP can bind to the binary RT primer/template complex. We looked for changes in kinetic parameters for dATP incorporation in the presence of a fixed concentration of 60 M GS-9148-DP. If the analogue were able to compete with the natural substrate for binding, we would expect to see further increases in K d values. However, incorporation of dATP was unaffected by the presence of GS-9148-DP. Knowing that any product formation observed would not represent the incorporation of GS-9148-DP under these conditions, we conclude that binding of the inhibitor is severely compromised by the Q151L mutation. The related Q151M mutation showed only low levels of resistance to the three inhibitors.
Modeling of GS-9148-DP binding to Q151L-containing RT. The crystal structure of WT RT bound to a DNA/DNA primer template and incoming GS-9148-DP has recently been solved (18) . This structure was used as a scaffold to model the binding of GS-9148-DP to Q151L-and Q151M-containing RT (Fig. 3) . In the WT and Q151M RT models, GS-9148-DP fits within the NRTI binding pocket and lacks negative interactions with RT. In contrast, the model generated for Q151L RT shows the development of a negative steric interaction between the 2Ј-fluoro moiety of GS-9148-DP and the side chain of the Q151L mutant. a Errors reported represent the deviation of points from the curve fit generated by GraphPad Prism (version 5.0). Standard deviations from four independent experiments with WT RT for the incorporation of dATP were 15% for k pol and 34% for
SAR experiments with 2-modified adenosine analogues. To further investigate the potential role of the 2Ј-fluoro group in the diminished binding of GS-9148-DP to the Q151L mutant RT, we included additional related adenosine analogues in our inhibition studies (Fig. 4A) . The analogues used were araATP, 2Ј-azido-2Ј-dATP, and 2Ј-fluoro-2Ј-dATP. These compounds differ from GS-9148-DP in that they contain a standard phosphoester link rather than the phosphonate moiety that is present in GS-9148-DP and tenofovir-DP. Rigorous kinetic analysis, such as pre-steady-state kinetics, was limited due to the poor overall incorporation of these substrates, which are actively incorporated only at high concentrations, as described for ATP. An assessment at a single concentration of 1 mM and a single time point revealed structurally related trends across the panel of mutant RTs. Incorporation of 2Ј-modified substrates at 1 mM was normalized against the incorporation of 1 M natural substrate dATP for each enzyme. Under this type of analysis, araATP was mostly unaffected by the different mutants compared to the WT, with relative efficiencies in the order Q151M mutant Ͼ WT Ͼ Q151L mutant Ͼ K65R mutant. 2Ј-azido-2Ј-dATP was strongly disfavored for incorporation by all enzymes, including WT RT. 2Ј-fluoro-2Ј-dATP was incorporated by the WT at levels similar to araATP and was strongly disfavored by the Q151L mutant. The pattern is similar to that seen with GS-9148-DP, which points to an important role of the 2Ј-fluoro-group in determining resistance in the context of the Q151L mutant.
Nucleotide excision by the Q151L mutant. Our pre-steadystate kinetic analysis shows that the Q151L mutant is fully sensitive to tenofovir-DP. Selectivity values for WT and Q151L mutant RT are almost identical; thus, these findings do not explain the hypersusceptible phenotype observed in cell culture (16) . However, resistance-conferring mutations may not discriminate against the inhibitor only at the level of incorporation, as thymidine analogue-associated mutations (TAMs) in HIV-1 RT have also been shown to increase rates of excision in the presence of PP i or the pyrophosphate donor ATP to mediate NRTI resistance (1, 24) . Conversely, many other known mutations, including M184V (lamivudine resistance) (13), L74V (didanosine resistance) (11, 26) , and K65R (resistance to multiple nucleotide analogues) (25, 27, 33) , have been shown to diminish the efficiency of excision and cause hypersusceptibility to the thymidine analogue zidovudine (33) .
Therefore, we assessed the ability of WT RT and the K65R and Q151L mutants to perform ATP-and PP i -mediated excision of tenofovir, with the hypothesis that hypersusceptibility could be mediated through decreased efficiency of the excision reaction. Of note, GS-9148-DP was not excised at a physiologically relevant concentration of 3.2 mM ATP, either with WT RT or with the K65R or Q151L mutant (data not shown). The rates of ATP-mediated excision of tenofovir-DP were seen to be very similar between the WT and the Q151L mutant, at 0.010 ϫ 10 Ϫ4 Ϯ 3.6 ϫ 10 Ϫ4 min Ϫ1 and 0.011 ϫ 10 Ϫ4 Ϯ 3.2 ϫ 10 Ϫ4 min Ϫ1 , respectively. With a rate of 9.8 ϫ 10 Ϫ4 Ϯ 1.1 ϫ 10 Ϫ4 min Ϫ1 , the K65R mutant was compromised relative to the WT and the Q151L mutant. In contrast to the results obtained FIG. 3 . Molecular models of WT and mutant RT enzymes bound to primer/template and GS-9148-DP. The structure of WT HIV-1 RT bound to primer/template and GS-9148-DP served as a basis for models with mutations at position Q151 (18) (A). Models for the Q151L (B) and Q151M (C) mutants were generated as described in Materials and Methods. A steric clash between the 2Ј-fluoro moiety of GS-9148-DP (2ЈF) and the side chain of the Q151L mutant is highlighted. with ATP, similar time course experiments with PP i revealed differences in excision between WT and Q151L mutant RT. We further examined these differences using the same analysis as employed for the forward reaction to determine the maximum rate of pyrophosphorolysis, k pyro , and the equilibrium binding constant, K d-PPi . While WT RT and the K65R and Q151L mutants show similar values for the rate constant (k pyro ), the Q151L and K65R mutants show 6-fold and 10-fold reductions in affinity to PP i (K d-PPi ), respectively ( Table 2 ). With no difference in rate constant, this decreased affinity to PP i translates directly to an overall 6-fold reduction in efficiency of the excision reaction for the Q151L mutant and explains the observed hypersensitivity to tenofovir.
DISCUSSION
The aim of this study was to elucidate the biochemical mechanisms of resistance to GS-9148 utilized by the HIV-1 Q151L mutant RT. The related Q151M mutation is known to confer resistance to multiple nucleoside analogues, with the exception of tenofovir (23) . Q151M is often associated with changes at positions 62, 75, 77, and 116 that appear to correct for deficiencies in replication capacity (15) . Cell-based assays revealed that Q151L confers resistance to GS-9148 and hypersusceptibility to tenofovir (16) . GS-9148 and tenofovir share the same base and phosphonate moieties, suggesting that structural differences in the sugar and the acyclic linker, respectively, can affect the phenotype. We have utilized primarily pre-steadystate kinetic tools to study whether these findings can be translated into biochemical terms.
The Q151L mutant shows an approximately 8-fold reduction in the efficiency of incorporation of the natural substrate dATP. This deficiency is driven by an increase in K d values that translates into a reduction in substrate affinity. Similar values are determined with the Q151M mutant, which provides an explanation for the diminished replication capacity of corresponding viruses (15, 21) . By comparison, the K65R mutant shows a 2-fold reduction that is driven by subtle differences in k pol values that translate into a deficiency of the rate of conformational closing of the thumb-and-finger loop domain (6) . The exact values may change, depending on the nature of the nucleotide substrate and the nature of the primer/template; however, similar trends have been reported for K65R and Q151M mutants (8, 10, 27) .
Changes in kinetic parameters for the nucleotide analogues reveal a more complex picture. For instance, the K65R mutant shows decreases in k pol values for GS-9148-DP and tenofovir-DP. The sharp decline in k pol values for tenofovir translates into more-efficient discrimination against this inhibitor (6-fold versus 3-fold). The Q151M mutant shows both decreases in k pol and increases in K d values for GS-9148-DP, tenofovir, and ddATP, with the greatest effect being a 6-fold decrease in k pol for ddATP. The overall effects of the Q151M mutation on the various inhibitors are generally subtle, however, after adjusting for changes seen with the natural dNTP substrate.
The effect of Q151L on the incorporation of GS-9148 is the most striking observation. The inhibitor is not incorporated under single-turnover conditions. This effect is highly specific, as the efficiency of incorporation of tenofovir is not reduced. Subtle decreases in k pol values and increases in K d values appear to be in balance. An interference experiment provides a plausible mechanism for the lack of incorporation of GS-9148. The presence of GS-9148-DP does not interfere with the efficiency of incorporation of dATP. Both kinetic parameters k pol and K d are almost identical when measured in the absence or presence of the inhibitor. Any increase in the K d value would have pointed to a certain degree of competition and, in turn, binding of the inhibitor to the active site. The insignificant change in the K d value for dATP suggests that Q151L severely compromises binding of the inhibitor. We cannot exclude an effect on the catalytic rate of incorporation of GS-9148 by Q151L in addition to impaired binding; however, binding is sufficiently diminished to prevent incorporation of GS-9148 in the presence of the natural substrate.
In an attempt to characterize the structural reasons for this type of discrimination, we studied the effects of Q151L on the kinetic efficiency of related compounds. The phosphonate in place of a phosphoester, the 2Ј-fluoro group, and the unsaturated 2Ј,3Ј double bond of the sugar moiety are the three structural determinants that distinguish GS-9148-DP from its natural counterpart dATP. We ruled out the phosphonate as an important factor in this regard, given that tenofovir is still efficiently incorporated by the Q151L mutant. We have therefore limited this analysis to several commercially available compounds with modifications at the 2Ј position of the ribose sugar. Y115 in HIV-1 RT appears to play an important role in discriminating between ribonucleotides and deoxyribonucleotides, and structural models suggest that the 2Ј-OH group appears to cause steric problems (3) . As a consequence, incorporation of ATP requires high concentrations and is inefficient when the preferred substrate dATP is present. We have made similar observations with araATP, 2Ј-azido-2Ј-dATP, and 2Ј-fluoro-2Ј-dATP. The bulky 2Ј-azido group shows the strongest effect in this regard, and incorporation is severely compromised by K65R, Q151L, and Q151M. Low levels of incorporation are seen solely with WT RT. In contrast, the pattern obtained with 2Ј-fluoro-2Ј-dATP is reminiscent of the data obtained with GS-9148-DP. The K65R and Q151M mutants show subtle reductions in GS-9148 incorporation, while the Q151L mutant completely prevents incorporation of the inhibitor. Together, these data point to a certain degree of structural homology between GS-9148 and 2Ј-fluoro-2Ј-dATP. The planar character of GS-9148 appears to bypass the steric problem with Y115 and facilitates its incorporation. The crystal structure of a complex of WT HIV-1 RT with primer/template and GS-9148-DP bound at the active site supports this notion and shows favorable interaction between the dihydrofuran ring of the inhibitor and the aromatic side chain of Y115 (18) . Although structures of the Q151L mutant, alone or with GS- 9148-DP, are not available, modeling based on the structure of WT RT in complex with GS-9148-DP points to a steric clash between the Q151L mutant and the 2Ј-fluoro group of GS-9148-DP (Fig. 3) . A steric clash is evident only with the Q151L mutant and is not seen in the Q151M mutant model, which could explain why the Q151M mutant displays near-wild-type selectivity for GS-9148-DP. The observed hypersusceptibility of the Q151L mutant to tenofovir is not explained by changes in incorporation, as both WT RT and the Q151L mutant display similar selectivities to the inhibitor relative to the natural substrate. Results from excision experiments with PP i suggest that hypersusceptibility is instead mediated through diminished excision of incorporated tenofovir. This is likely due to reduced binding of PP i with the Q151L mutant. The lack of any significant difference between WT RT and the mutants in the presence of ATP as the PP i donor could be the result of additional contacts, which dilutes the subtle effect on excision (32) .
Taken together, our biochemical studies show that mutants with resistance-conferring mutations at position Q151 in HIV-1 RT display only subtle reductions in the efficiency of incorporation of a structurally diverse set of adenosine analogues. The exception is the inability of the Q151L mutant to incorporate GS-9148. We present strong evidence to demonstrate that specificity is mediated through steric hindrance caused by modifications at the 2Ј position of the sugar moiety. However, the development of high-level resistance to GS-9148 in the context of the Q151L mutant is associated with a price in that the efficiency of incorporation of the natural dATP substrate is reduced to an extent similar to that seen with the related Q151M mutation. These findings help to explain the rare selection of the Q151L mutation in cell culture. The high barrier to resistance warrants further investigation into novel nucleotide analogues that are modified at the 2Ј position. Of note, potent 2Ј-modified nucleotides are being developed to target the RNA-dependent RNA polymerase of the hepatitis C virus (HCV) (28) . By analogy, the emergence of the signature mutation S282T is also associated with a high barrier in cell culture and in the clinic. To test whether the emergence of Q151L can be reduced further or even prevented, it is likewise of interest to study the interaction of Q151L in conjunction with other mutations that are selected in the presence of established drugs.
